Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 20, 1988 - Issue sup60
Submit an article Journal homepage
98
Views
1
CrossRef citations to date
0
Altmetric
Miscellany

Changing Trends in Antibiotic Therapy: Role of Ciprofloxacin

Carl Erik Nord
&
S. Ragnar Norrby
Pages 1-128 | Published online: 02 Jan 2015

References

  • Trollfors B, Alestig K, Krantz I, Norrby R. Quantitative nephrotoxicity of gentamicin in nontoxic doses. J Infect Dis 141: 306–309, 1980
  • Wallder M, Leandoer L, Törnqvist A, Forsgren A. Long-term effects on bacteral sensitivity pattern of preoperative antibiotic prophylaxis in colorectal surgery. Scand J Infect Dis Suppl. 53: 59–64, 1988
  • Urinary Tract Infection Study Group. Coordinated multicenter study of norfloxacin versus trimethoprimsulfamethoxazole treatment of symptomatic urinary tract infections. J Infect Dis 155: 170–177, 1987
  • Svensk Läkemedelsstatistik 1984, Apoteksbolaget, Stockholm, Sweden, 1985

References

  • Ronald AR, Turck M, Petersdorf RG. A critical evaluation of nalidixic acid in urinary tract infections. N Engl J Med 275: 1081–1089, 1966
  • Lumish RM, Norden CW. Cinoxacin: In vitro antibacterial studies of a new synthetic organic acid. Antimicrob Agents Chemother 7: 159–163, 1975
  • King A, Schammon L, Phillips I. The in vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. J Antimicrob Chemother, Suppl A: 25–39, 1986
  • Bauernfeind A, Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 2: 111–115, 1983
  • Digranes A, Dibb WL, Benonisen E. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim. Chemotherapy 31: 466–471, 1985
  • Forsgren A. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates. Scand J Infect Dis 17: 91–94, 1985
  • Bergan T, Lolekha S, Cheong MK, Poh CL, Doencham S, Charoenpipop D. Effect of recent antibacterial agents against bacteria causing diarrhoea. Scand J Infect Dis, Suppl. In press.
  • Olsson-Liljequist B. In vitro activity of ciprofloxacin against Bacteroides, Haemophilus influenzae and Branhamella catarrhalis. J Clin Microbiol 3( S4): 370–371, 1984
  • Digranes A. In vitro activity of amifloxacin (WIN 49 375) compared with these of ciprofloxacin and ofloxacin. Acta Pathol Microbiol Immunol Scand (B) 95: 29–32, 1987
  • Søgaard P, Arpi M, Gahrn-Hansen B. Ciprofloxacin og andre fluorokinoloner. Ugeskr Laeger 149: 2316–2319, 1987
  • Kaukoranta-Tolvanen SSE, Renkonen OVJ. In vitro susceptibility of Neisseria gonorrhoeae to RO 23-6240 and ciprofloxacin. Eur J Clin Microbiol 6: 315–317, 1987
  • Edlund C, Nord CE. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile. Scand J Infect Dis 18: 149–151, 1986
  • Zeiler HJ, Grohe K, Müller HJ, Hullmann R, Schacht P. The antibacterial activity of ciprofloxacin in vitro. In: Ciprofloxacin Product Monograph, Auckland, New Zealand, 33–41, 1986
  • Ratcliffe NT, Smith JT. The mechanism of reduced activity of 4-quinolone agents in urine. Fortschr Antimikrob Antineoplast Chemother 3–5: 563–569, 1984
  • Aoyama H, Sato K, Kato K, Hirai K, Mitsuhashi S. Norfloxacin resistance in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother 30: 777–780, 1986
  • Sato K, Inone Y, Fujii T, Aoyama H, Inone M, Mitsuhashi S. Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother 30: 777–780, 1986
  • Forsgren A, Striby AC. In vitro selection of Escherichia coli mutants with decreased susceptibility to norfloxacin. Scand J Infect Dis 20: 531–534, 1988
  • Eron LJ, Harvey L, Hixon DL, Poretz DM. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother 27: 308–310, 1985
  • Humphreys H, Mulvihill E. Ciprofloxacin-resistant Staphylococcus aureus. Lancet ii: 383, 1985
  • Søgaard P, Gahrn-Hansen B. Population analysis of susceptibility to ciprofloxacin and nalidixic acid in Staphylococcus, Pseudomonas aeruginosa, and Enterobacteriaceae. Acta Pathol Microbiol Immunol Scand (B) 94: 351–356, 1986
  • Gerner-Smidt P, Fuursted K. Population analyses of the susceptibility to ciprofloxacin of eight clinical strains of Pseudomonas aeruginosa. Acta Pathol Microbiol Immunol Scand (B) 94: 273–276, 1986
  • Gahrn-Hansen B, Søgaard P, Arpi M. In vitro activity of ciprofloxacin against methicillin-susceptible and methicillin-resistant staphylococci. Eur J Clin Microbiol 6: 581–584, 1987
  • Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 25: 319–326, 1984
  • Zeiler HJ, Grohe K. The in vitro and in vivo activity of ciprofloxacin. Eur J Clin Microbiol 3: 339–343, 1984
  • Eliopoulos GM, Gardella A, Moellering Jr RC. In vitro activity of ciprofloxacin, a new carboxy-quinoline antimicrobial agent. Antimicrob Agents Chemother 25: 331–335, 1984
  • Reeves DS, Bywater MJ, Holt HA. In vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother 13: 333–346, 1984
  • Rudin JE, Norden CW, Shinners EM. In vitro activity of ciprofloxacin against aerobic Gram-negative bacteria. Antimicrob Agents Chemother 26: 597–598, 1984
  • Chapman ST, Speller DCE, Reeves DS. Resistance to ciprofloxacin. Lancet ii: 39, 1985
  • Eron LJ, Harvey L, Hixon DL. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother 27: 308–310, 1985
  • Follath F, Bindschedler M, Wenk M. Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 5: 236–240, 1986
  • Giamarellou H, Galanakis N, Dendrinos C. Evaluation of ciprofloxacin in treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 5: 232–235, 1986
  • Roberts CM, Batten J, Hodson ME. Ciprofloxacin-resistant Pseudomonas. Lancet i: 1442, 1985
  • Fuursted K, Gerner-Smidt P. Analysis of the interaction between piperacillin and ciprofloxacin or tobramycin against thirteen strains of Pseudomonas aeruginosa, using killing curves. Acta Pathol Microbiol Immunol Scand (B) 95: 193–197, 1987
  • Bigger JW. The bacterial action of penicillin on Staphylococcus pyogenes. Ir J Med Sci 227: 553–568, 1944
  • Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Post-antibiotic suppression of bacterial growth. Rev Infect Dis 3: 28–37, 1981
  • McDonald PJ, Craig WA, Kunin CM. Brief antibiotic exposure and effect on bacterial growth. Chemotherapy 2: 95–102, 1976
  • McDonald PJ, Craig WA, Kunin CM. Persistent effect of antibiotics on Staphylococcus aureus after exposure of limited periods of time. J Infect Dis 135: 217–223, 1977
  • Bodey GP, Pan T. Effect of cephalothin on growth patterns of micro-organisms. J Antibiot 29: 1092–1095, 1976
  • Fuursted K. Post-antibiotic effect and killing activity of ciprofloxacin against Staphylococcus aureus. Acta Pathol Microbiol Immunol Scand (B) 95: 199–202, 1987
  • Fuursted K. Post-antibiotic effect of ciprofloxacin on Pseudomonas aeruginosa. Eur J Clin Microbiol 6: 271–274, 1987

References

  • Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med 306: 1081–1088, 1982
  • Guay DRP, Auni WM, Peterson PK, Obaid S, Breitenbacher R, Matzke GR. Pharmacokinetics of ciprofloxacin in acutely ill and convalescent patients. Am J Med 82 ( Suppl. 4A): 124–129, 1987
  • Ball AP, Fox C, Ball ME, Brown IRF, Willis JV. Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. J Antimicrob Chemother 17: 629–635, 1986
  • Bayer A, Gajewska A, Stephens M, Stark JM, Pathy J. Pharmacokinetics of ciprofloxacin in the elderly. Respiration 51: 292–295, 1987
  • LeBel M, Barbeau G, Bergeron MG, Roy D, Vallée F. Pharmacokinetics of ciprofloxacin in elderly subjects. Pharmacother 6: 87–91, 1986
  • LeBel M. Pharmacokinetic behaviour of fluoroquinolones in the elderly. Quinolones Bulletin 4: 9–11, 1988
  • Drusano GL. An overview of the pharmacology of intravenously administered ciprofloxacin. Am J Med 82 ( Suppl. 4A): 339–345, 1987
  • Beerman D, Scholl H, Wingender W, Förster D, Beubler E, Kukovetz WR. Metabolism of ciprofloxacin in man. In: Neu, H, ed. 1st international ciprofloxacin workshop. Amsterdam: Excerpta Medica, 141–146, 1986
  • Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of antimicrobial agents in the elderly. Rev Infect Dis 9: 250–264, 1987
  • Ljungberg B, Nilsson-Ehle I. Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients. Eur J Clin Pharmacol 34: 173–178, 1988

References

  • Ylikoski J. Correlative studies on the cochlear pathology and hearing loss in guinea pigs after intoxication with ototoxic antibiotics. Acta Otolaryngol (Stockh) Suppl. 326, 1975
  • Lundquist P-G, Wersäll J. Kanamycin-induced changes in cochlear hair cells of the guinea pig. Z Zellforsch 72: 543, 1966
  • Anniko M, Bagger-Sjöbäck D, Wersäll J, Schacht J. Gentamicin binding to the isolated crista ampullaris of the guinea pig. Res Commun Chem Pathol Pharmacol 37: 333–342, 1982
  • Forge A. Observations on the stria vascularis of the guinea pig and the changes resulting from the administration of the diuretic furosemide. Clin Otolaryngol 1: 211–219, 1976
  • Brummett RE, Fox KE, Brown RJ, Himes DL. Comparative ototoxic liability of netilmicin and gentamicin. Arch Otolaryngol 104: 579–584, 1978
  • Johansson L-G, Hawkins JE Jr, Kingsley TC, Black FO, Matz GJ. Aminoglycoside-induced cochlear pathology in man. Acta Otolaryngol Suppl. 383: 3–19, 1981
  • Brown RD. Ototoxicity caused by ethacrynic acid and furosemide. Minerva Otolaryngol 22: 213–221, 1973
  • Rybak LP. Ototoxic mechanisms. In: Altschuler RA, Hoffman DW, Bobbin RP, eds. Neurobiology of hearing: the cochlea. New York: Raven Press, 441–454, 1986
  • Engström B. Stereocilia of sensory cells in normal and hearing impaired ears. A morphological, physiological and behavioural study. Thesis Scand Audiol Suppl. 19, 1983
  • Wersäll J, Björkroth B, Flock Å, Lundquist P-G. Sensory hair fusion in vestibular sensory cells after gentamicin treatment. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 200: 1, 1971
  • Bagger-Sjöbäck D, Wersäll J. Toxic effects of gentamicin on the basilar papilla in the lizard calotes versicolor. A surface study. Acta Otolaryngol 81: 57–65, 1976
  • Pike D, Bosher SK. The time course of the strial changes produced by intravenous furosemide. Hearing Res 3: 79–89, 1980

References

  • Lahnborg G, Hedström KG, Nord CE. Efficacy of different antibiotics in the treatment of experimentally induced intraabdominal sepsis. J Antimicrob Chemother 10: 497–504, 1982
  • Forsgren A. Overview of Scandinavian in vitro studies with ciprofloxacin. Scand J Infect Dis, Suppl. 60: 16–22, 1989
  • Nord CE, Heimdahl A, Kager L, Malmborg AS. The impact of different antimicrobial agents on the normal gastrointestinal microflora of humans. Rev Infect Dis 6: S270–S275, 1984

References

  • Gellert M, Mizuuchi K, O'Dea MH, Nash HA. DNA gyrase: An enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA 73: 3871–3876, 1976
  • Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa J-I. Nalidixic acid and resistance: A second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 74: 4772–4776, 1977
  • Wang JC. DNA topoisomerases. Ann Rev. Biochem 54: 665–697, 1985
  • Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of the drugs is DNA. Proc Natl Acad Sci USA 82: 307–311, 1985
  • Easmon CSF, Crane JP. Uptake of ciprofloxacin by macrophages. J Clin Pathol 38: 442–444, 1985
  • Hussy P, Maas G, Tümmler B, Grosse F, Schamburg. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha complex, topoisomerase I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother 29: 1073–1078, 1986
  • McClure WR. Mechanism and control of transcription initiation in prokaryotes. Ann Rev Biochem 54: 171–204, 1985
  • Castora FJ, Vissering FF, Simpson MV. The effect of bacterial DNA gyrase inhibitors on DNA synthesis in mammalian mitochondria. Biochim Biophys Acta 740: 417–427, 1983
  • Forsgren A, Schlossman SF, Tedder TF. 4-quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro. Antimicrob Agents Chemother 31: 768–773, 1987
  • Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF. Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth. Antimicrob Agents Chemother 31:774–779, 1987
  • Someth E, Schwartz E, Rubinstein E. The effect of pefloxacin and ciprofloxacin on bone marrow grafting in mice. 27th ICAAC 1987; Abstr 31.
  • Forsgren A, Bergh A-K, Brant M, Hansson G. Quinolones affect thymidine incorporation into the DNA of human lymphocytes. Antimicrob Agents Chemother 29: 506–508, 1986
  • Bredberg A, Brant B, Riesbeck K, Azou Y, Forsgren A. 4-Quinolone antibiotics: Positive genotoxic screening tests despite an apparent lack of mutation induction. Mutat Res 211: 171–180, 1989
  • McQueen CA, Williams GM. Effects of quionolone antibiotics in tests for genotoxicity. Am J Med 82 ( Suppl 4 A): 94–96, 1987
  • Schlüter G. Toxicology of quinolones. Fortschritte der antimikrobiellen und antineoplastischen Chemoterapie. Band 6–10: 1631–42, 1987
  • Kohn KW. DNA as a target in cancer therapy: Measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens. Methods Cancer Res 16: 291–345, 1979
  • Mayer DG. Mutagenitätsbefunde. Fortschritte der antimikrobiellen und antineoplastischen Chemoterapie. Band 6–10: 1043–55, 1987
  • Mitelman F, Kolnig A-M, Strömbeck B, Norrby R, Kromann-Andersen B, Sommer P, Wadstein J. No cytogenetic effects of quinolone treatment in humans. Antimicrob Agents Chemother 32: 936–937, 1988
  • Riesbeck, K, Andersson J, Gullberg M, Forsgren A. Fluorinated 4-quinolones induce hyperproduction of interleukin-2. Proc Natl Acad Sci USA 86: 2809–2813, 1989
  • Shaw J, Meerovitch K, Bleackley CR, Paetkau V. Mechanisms regulating the level of IL-2 mRNA in T lymphocytes. J Immunol 140: 2243–2248, 1988

References

  • Bauernfeind A, Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 2: 111–115, 1983
  • Fass RJ. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother 24: 568–574, 1983
  • Chin N-X, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 25: 319–324, 1984
  • Barry AL, Jones RN, Thornsberry C, Ayers LW, Gerlach EH, Sommers HM. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother 25: 633–637, 1984
  • Forsgren A. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates. Scand J Infect Dis 17: 91–94, 1985
  • Crump B, Wise R, Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 24: 784–786, 1983
  • Gonzales MA, Uribe F, Moisen SD, Fuster AP, Selen A, Welling PG, Painter B. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26: 741–744, 1984
  • Höffken G, Lode H, Prinzing C, Borner K, Koeppe P. Pharmacokinetics of ciprifloxacin after oral and parenteral administration. Antimicrob Agents Chemother 27: 375–379, 1985
  • Davis RL, Koup JR, Williams-Warren J, Weber A, Smith AL. Pharmacokinetics of three oral formulation of ciprofloxacin. Antimicrob Agents Chemother 28: 74–77, 1985
  • Kronvall G. Analysis of a single reference strain for determination of gentamicin regression line constants and inhibition zone diameter breakpoints in quality control disk diffusion antibiotic susceptibility testing. J Clin Microbiol 16: 784–793, 1982
  • Ericsson HM, Sherris JC. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand (B), Suppl. 217: 1–90, 1971
  • Schmidt L. The MIC50/MIC90 assessments of in vitro activities of antimicrobial agents that facilitates comparative agent-agent and agent-species susceptibility comparisons. Antimicrob News 4: 1–8, 1987
  • Cooper KE, Woodman D. The diffusion of antiseptics through agar gels, with special references to the agar cup assay method of estimating the activity of penicillin. J Pathol Bacteriold 58: 75–84, 1946
  • Ringertz S, Kronvall G. On the theory of the disk diffusion test. Evidence for a non-linear relationship between critical concentration and MIC, and its practical implications for susceptibility testing of Haemophilus influenzae. Acta Pathol Microbiol Immun Scand 96: 484–490, 1988
  • Hare RS, Miller GH. Susceptibility testing of aminoglycosides. In: Aminoglycoside antibiotics: A guide to therapy. CRC Press Inc. Boca Raton, 182–200, 1984
  • Huovinen P, Herva E, Katila M-J, Klossner M-L, Renkonen O-V, Toivonen P. Reliability of a disk diffusion method using semiconfluent growth in the determination of aminoglycoside resistance. Acta Pathol Microbiol Scand (B), 94: 153–157, 1986
  • National Committee for Clinical Laboratory Standards: Performance standards or antimicrobial susceptibility testing. National Committee for Clinical Laboratory Standards, Villanova, Pa., Suppl. 1987

References

  • Tolkhoff-Rubin NE, Rubin RH. New approaches to the treatment of urinary tract infection. Am J Med 82 ( Suppl 4A): 270–277, 1987
  • Høiby N. Clinical uses of nalidixic acid analogoues: The fluoro-quinolones. Eur J Clin Microbiol 5: 138–140, 1986
  • Zeiler H-J, Beermann D, Wingender W, Förster D, Schacht P. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection 16 ( Suppl 1): 19–23, 1988
  • Dalhoff A, Weidner W. Diffusion of ciprofloxacin into prostatic fluid. Eur J Clin Microbiol Infect Dis 7: 438–439, 1988
  • Bergan T, Dalhoff A, Rohwedder R. Pharmacokinetics of ciprofloxacine. Infection 16 ( Suppl 1): 3–13, 1988
  • Daschner FD, Westenfelder M, Dalhoff A. Penetration of ciprofloxacin into kidney, fat, muscle and skin tissue. Eur J Clin Microbiol 5: 121–213, 1986
  • Grabe M, Forsgren A, Björk T. Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection. Eur J Clin Microbiol 5: 211–212, 1986
  • Neu HC. Infection today. Clinical use of the quinolones. Lancet ii: 1319–1322, 1987
  • Schacht P, Arcieri G, Ranolte J, Bruck H, Chysky V, Gruenwaldt G, Hullman R, Konopka CA, O'Brian B, Rahm V, Rycki T, Westwood A, Weuta H. Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection 16 ( Suppl 1): 29–43, 1988
  • Weidner W, Scheifer HG. Treatment of chronic bacterial prostatitis with ciprofloxacin. Am J Med 82 ( Suppl 4A): 280–283, 1987
  • Peters HJ. Comparison of intravenous ciprofloxacin and mezlocillin in treatment of complicated urinary tract infection. Eur J Clin Microbiol 5: 253–255, 1986
  • Gasser TC, Graversen PH, Madsen PO. Treatment of complicated urinary tract infections with ciprofloxacin. Amer J Med 82 ( Suppl 4A): 278–279, 1987
  • Goldstein ECJ, Kahn RM, Albert ML, Ginsberg BP, Greenway FL, Citron DM. Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial. Amer J Med 82 ( Suppl 4A): 284–287, 1987
  • Henry NK, Schultz HJ, Grubbs NC, Muller SM, Ilstrup DM, Wilson WR. Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. J Antimicrob Chemother 18 ( Suppl D): 103–106, 1986
  • Williams AH, Grüneberg RN. Ciprofloxacin and co-trimoxazole in urinary tract infection. J Antimicrob Chemother 18 ( Suppl D): 107–110, 1986
  • Newsom SWB, Murphy P, Matthews J. A comparative study of ciprofloxacin and trimetroprim in the treatment of urinary tract infections in geriatric patients. J Antimicrob Chemother 18 ( Suppl D): 111–115, 1986
  • Polubiec A, Weuta H, Stepka K, Ktos K, Strazynska R, Jorasz J. Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin–a comparative study. Infection 16 ( Suppl 1): 62–64, 1988
  • Garlando R, Rietiker S, Tauber MG, Flepp M, Meier B, Lüthy R. Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother 31: 354–356, 1987
  • Kromann-Andersen B, Sommer P, Pers C, Larsen V, Rasmussen F. Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections. Infection 14 ( Suppl 4): 305–306, 1986
  • Allais JM, Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Randomized, double-blind comparison of ciprofloxacin and trimetropim-sulfamethoxazole for complicated urinary tract infections. Antimicrob Agents Chemother 32: 1327–1330, 1988

References

  • Oriel JD. Ciprofloxacin in the treatment of gonorrhoea and non-gonococcal urethritis. J Antimicr Chemother Suppl. D. 18: 129–132, 1986
  • Belli L, Castro JM, Casco R. Ciprofloxacin in the treatment of non complicated gonococcal urethritis. 14th International Congress of Chemotherapy, Kyoto, Abstr P–38–98, 1985
  • Hook EW, Roddy RE, Handsfield HH. Comparative trial of ciprofloxacin versus ampicillin and probenecid for the treatment of uncomplicated gonorrhoea in men. Presented at the 25th Inter-science Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, 1985
  • Oriel JD, Loo PS, Ridgway GL (personal communication).
  • Stolz E, Tegelberg-Stassen JCS vd Hoek, Wagenvoort JHT. Clinical efficacy of ciprofloxacin in gonorrhoea. Proc Exc Med, Ser 34, pp. 336–337, 1985
  • Perea EJ, Prados R, Miguel de C, Aznar J. Single-dose ciprofloxacin treatment of gonococcal urethritis. Proc Exc Med, Ser 34, pp. 338–341; 1985
  • Lassus A, Allgulander C, Juvakoski T. Efficacy of rosaramicin and tetracycline in chlamydia-positive and -negative non-gonococcal urethritis. Eur J Sex Transm Dis 1: 29–31, 1982
  • Reyn A, Korner B, Bentzon MW. Effects of penicillin, streptomycin, and tetracycline on N. gonorrhoeae isolated in 1944 and in 1957. Brit J Vener Dis 48: 517–521, 1958

References

  • Felman YM, Mphil MA, Nikitas JA. Nongonococcal urethritis. A clinical review. JAMA 245: 381–386, 1981
  • Bowie ER. Etiology and treatment of nongonococcal urethritis. Sex Transm Dis 5: 27–33, 1978
  • Jaffe HW. Nongonococcal urethritis: Treatment of men and their sexual partners. Rev Infect Dis 4: 772–777 ( Supp.), 1982
  • Hart CA, How SJ, Hobson D. Activity of ciprofloxacin against genital tract pathogens. Br J Vener Dis 60: 316–318, 1984
  • Peeters M, Van Dyck E, Piot P. In vitro acitivities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoea. Antimicrob Agents Chemother 26: 608–609, 1984
  • Loo PS, Ridgway GL, Oriel JD. Single dose ciprofloxacin for treating gonococcal infections in men. Genitourin Med 61: 302–305, 1985
  • Heessen FWA, Muytjens JL. In vitro acitivities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin and nalidix acid against Chlamydia trachomatis. Antimicrob Agents Chemother 25: 123–124, 1984
  • Ridgway GL, Mumtaz G, Gabriel FG, Oriel JD. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and mycoplasmas in vitro. Eur J Clin Microbiol 3: 334–346, 1984
  • Juvakoski T, Allgulander C, Lassus A, Rosaramicin and tetracycline treatment in Chlamydia trachomatis—positive and—negative nongonococcal urethritis. Sex Transm Dis 8: 12–15, 1981
  • Fong IW, Litton W, Simbul M, Thorup R, McLaughlin B, Rahm W, Quinn PA. Treatment of nongonococcal urethritis with ciprofloxacin. Am J Med 82: 311–316 ( Suppl), 1987

References

  • Heinonen PK, Teisala K, Punnonen R, Miettinen A, Lehtinen M, Paavonen J. Anatomic sites of upper genital tract infection. Obstet Gynecol 66: 384–390, 1985
  • Sweet RL, Mills J, Hadley KW, Blumenstock E, Schachter J, Robbie MO, Draper DL. Use of laparoscopy to determine the microbiologic etiology of acute salpingitis. Am J Obstet Gynecol 134: 68–74, 1979
  • Miettinen A. Mycoplasma hominis in patients with pelvic inflammatory disease. Isr J Med Sci 23: 713–716, 1987
  • Brihmer C, Kallings I, Nord CE, Brundin J. Salpingitis; aspects of diagnosis and etiology: A 4-year study from a Swedish capital hospital. Eur J Obstet Gynecol Reprod Med 24: 211–220, 1987
  • Mårdh P-A, Møller BR, Paavonen J. Chlamydial infection of the female genital tract with emphasis on pelvic inflammatory disease. A review of Scandinavian studies. Sex Transm Dis 8 ( Suppl): 140–155, 1981
  • Gjønnaes H, Dalaker K, Ånestad G, Mård P-A, Kvile G, Bergan T. Pelvic inflammatory disease: Etiologic studies with emphasis on chlamydial infection. Obstet Gynecol 59: 550–555, 1982
  • Paavonen J, Teisala K, Heinonen PK, Aine R, Laine S, Lehtinen M, Miettinen A, Punnonen R, Grönroos P. Microbiological and histopathological findings in acute pelvic inflammatory disease. Br J Obstet Gynaecol 94: 454–460, 1987
  • Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 138: 880–892, 1980
  • Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35: 373–447, 1988
  • Hart CA, How SJ, Hobson D. Activity of ciprofloxacin against genital tract pathogens. Br J Vener Dis 60: 316–318, 1984
  • Aznar J, Caballero MC, Lozano MC, de Miguel C, Palomares JC, Perea EJ. Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother 27: 76–78, 1985
  • Ridgway GL, Mumtaz G, Gabriel FG, Oriel JD. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and mycoplasmas in vitro. Eur J Clin Microbiol 3: 344–346, 1984
  • Schachter J, Moncada J. In vitro activity of ciprofloxacin against Chlamydia trachomatis. Am J Med 82 ( Suppl 4A): 42–43, 1987
  • Paavonen J, Aine R, Teisala K, Heinonen PK, Punnonen R, Lehtinen M, Miettinen A, Grönroos P. Chlamydial endometritis. J Clin Pathol 38: 726–732, 1985
  • Ripa KT, Mårdh P-A. Cultivation of Chlamydia trachomatis in cycloheximide-treated McCoy cells. J Clin Microbiol 6: 328–332, 1977
  • Lehtinen M, Rantala I, Teisala K, Heinonen PK, Lehtinen T, Aine R, Miettinen A, Grönroos P, Punnonen R, Leinikki P, Paavonen J. Detection of Herpes simplex virus in women with acute pelvic inflammatory disease. J Infect Dis 152: 78–82, 1985
  • Hager WD, Eschenbach DA, Spence MR, Sweet RL. Criteria for diagnosis and grading of salpingitis. Obstet Gynecol 61: 113–114, 1983
  • McCormack WM, Nowroozi K, Alpert S, Sackel SG, Lee Y, Lowe EW, Rankin JS. Acute pelvic inflammatory disease. Characteristics of patients with gonococcal and nongonococcal infection and evaluation of their response to treatment with aqueous procaine penicillin G and spectinomycin hydrochloride. Sex Transm Dis 4: 125–131, 1977
  • Goormans E, Dalhoff A, Kazzaz B, Branolte J. Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration. Chemotherapy 32: 7–17, 1986
  • Gerstner GJ, Dalhoff A, Weuta H. Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues. Infection 16 ( Suppl 1): S24–S28, 1988
  • Ahmed-Jushuf IH, Arya OP, Hobson D, Pratt BC, Hart CA, How SJ, Tait IA, Rao PMS. Ciprofloxacin treatment of chlamydial infections of urogenital tracts of women. Genitour Med 64: 14–17, 1988
  • Hoyme UB, Buhler K, Schindler AE. Chlamydial infection in women with laparoscopically diagnosed salpingitis and tubal infertility: Preliminary results of treatment of salpingitis with ciprofloxacin. In: Proceedings of the European Society for Chlamydia Research. Bologna: Esculapio, 210, 1988
  • Heinonen PK, Teisala K, Punnonen R, Aine R, Lehtinen M, Miettinen A, Paavonen J. Treating pelvic inflammatory disease with doxycycline and metronidazole or penicillin and metronidazole. Genitour Med 62: 235–239, 1986
  • Centers for Disease Control. Antibiotic-resistant strains of Neisseria gonorrhoeae. MMWR 36 ( Suppl 5S): 1S–18S, 1987
  • Thompson SE, Brooks C, Eschenbach DA, Spence MR, Cheng S, Sweet R, McCormack WM. High failure rates in outpatient treatment of salpingitis with either tetracycline alone or penicillin/ampicillin combination. Am J Obstet Gynecol 152: 635–641, 1985
  • Chow AW, Malkasian KL, Marshall JR, Guze LB. The bacteriology of acute pelvic inflammatory disease: Value of cul-de-sac cultures and relative importance of gonococci and other aerobic or anaerobic bacteria. Am J Obstet Gynecol 122: 876–879, 1975
  • Eschenbach DA, Buchanan TM, Pollock HM, Forsyth PS, Alexander ER, Lin J-S, Wang S-P, Wentworth BB, McCormack WM, Holmes KK. Polymicrobial etiology of acute pelvic inflammatory disease. N Engl J Med 293: 166–171, 1975
  • Hägele D, Chysky V. Is pelvic inflammatory disease an indication for treatment with ciprofloxacin? Infection 16 ( Suppl 1): S48–S50, 1988
  • Sweet RL, Yonekura ML, Hill G, Gibbs RS, Eschenbach DA. Appropriate use of antibiotics in serious obstetric and gynecologic infections. Am J Obstet Gynecol 146: 719–739, 1983
  • Teisala K, Heinonen PK, Punnonen R. Laparoscopic diagnosis and treatment of acute pyosal-pinx. J Reprod Med 1989 (in press).

References

  • Barry AL, Jones RN, Thornsberry C, Ayers LW, Gerlach EH, Sommers HM. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother 25: 633–637, 1984
  • Norden CW, Shinners E. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. J Infect Dis 151: 291–294, 1985
  • Etesse H, Garraffo R, Dellamonica P, Bernard E. Diffusion of ciprofloxacin, ofloxacin, and pefloxacin in bone tissue. Rev Infect Dis 10 ( Suppl. 1): S185–186, 1988
  • Greenberg RN, Kennedy DJ, Reilly PM, Luppen KL, Weinardt WJ, Bollinger MR, Aguirre F, Kodesh F, Saeed AMK. Treatment of bone joint and soft tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother 31: 151–155, 1987
  • Swedish Study Group. Therapy of acute and chronic Gram-negative osteomyelitis with ciprofloxacin. J Antimicrob Chemother 22: 221–228, 1988
  • Greenberg RN, Tice AD, Marsh PK, Craven PC, Reilly PM, Bollinger M, Weinandt WJ. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med 82 ( Suppl. 4A): 266–269, 1987
  • Trexler Hessen M, Ingerman MJ, Kaufman DH, Weiner P, Santoro J, Korzeniowski OM, Boscia J, Topiel M, Bush LM, Kaye D, Levison ME. Clinical efficacy of ciprofloxacin therapy for Gram-negative bacillary osteomyelitis. Am J Med 82 ( Suppl. 4A): 262–265, 1987
  • Slama TS, Misinski J, Sklar S. Oral ciprofloxacin therapy for osteomyelitis caused by aerobic Gram-negative bacilli. Am J Med 82 ( Suppl. 4A): 259–261, 1987
  • Gilbert DN, Tice AD, Marsh PK, Craven PC, Preheim LC. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic Gram-negative bacilli. Am J Med 82 ( Suppl. 4A): 254–258, 1987
  • Lesse AJ, Freer C, Salata RA, Francis JB, Scheld WM. Oral ciprofloxacin therapy for Gram-negative bacillary osteomyelitis. Am J Med 82 ( Suppl. 4A): 247–253, 1987
  • Tice AD, Marsh PK, Craven PC. Ciprofloxacin administered orally as therapy for osteomyelitis. Rev Infect Dis 10 ( Suppl. 1): S187, 1988
  • Ramirez CA, Bran JL, Mejia CR, Gracia JF. Open, prospective study of the clinical efficacy of ciprofloxacin. Antimicrob Agents Chemother 28: 128–132, 1985
  • Mitelman F, Kolnig AM, Strömbäck B, Norrby R, Kromann-Andersson B, Sommer P, Wadstein J. No cytogenic effects of quinolone treatment in humans. Antimicrob Agents Chemother 32: 936–937, 1988
  • Campoli-Richard DM, Monk JP, Price A, Benfield P, Todd PA, Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35: 373–447, 1988

References

  • Anderson E, Hansson C, Swanbeck G. Leg and foot ulcers. An epidemiological survey. Acta Derm Venereol (Stockh) 64: 227–232, 1984
  • Monk BE, Sarkany I. Outcome of treatment of venous ulcers. Clin Exp Dermatol 7: 397–400, 1982
  • Hansson C, Andersson E, Swanbeck G. A follow-up study of leg and foot ulcer patients. Acta Derm Venereol (Stockh) 67: 496–500, 1987
  • Kontiainen S, Rinne E. Bacteria in ulcera crurum. Acta Derm Venereol (Stockh) 68: 240–244, 1988
  • Eriksson G, Eklund A-E, Kallings LO. The clinical significance of bacterial growth in venous leg ulcers. Scand J Infect Dis 16: 175–180, 1984
  • Witkowski JA, Parish LC. Cutaneous ulcer therapy. Int J Dermatol 25: 420–426, 1986
  • Wolfson JS, Hooper DC. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 28: 581–586, 1985
  • Lennette EH, Balows A, Houster WJ Jr, Shadomy HJ, eds. Manual of Clinical Microbiology, 4th edn. Washington, DC: American Society for Microbiology, 1985

References

  • Høiby N, Friis B, Jensen K, Koch C, Møller NE, Støvring S, Szaff M. Antimicrobial chemotherapy in cystic fibrosis patients. Acta Paediatr Scand, Suppl. 301: 75–100, 1982
  • Klinger JD, Aronoff SC. In vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. J Antimicrob Chemother 15: 679–684, 1985
  • Neu HC. Ciprofloxacin: An overview and prospective appraisal. Am J Med 82, Suppl 4A: 395–404, 1987
  • Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med 82, Suppl 4A: 180–184, 1987
  • Rubio TT. Ciprofloxacin: Comparative data in cystic fibrosis. Am J Med 82, Suppl 4A: 185–188, 1987
  • Jensen T, Pedersen SS, Høiby N, Koch C. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. Eur J Clin Microbiol 6: 618–622, 1987
  • Smith MJ, Hodson ME, Batten JC. Ciprofloxacin in cystic fibrosis. Lancet i: 1103, 1986
  • Ericsson A, Freyschuss U, Troell S, Strandvik B. Relation between clinical and roentgenological scores and measures of lung function in cystic fibrosis; with special reference to pulmonary 133Xenon elimination. Clin Physiol 7: 275–82, 1987
  • Shwachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis. Am J Dis Child 96: 6–15, 1958
  • Gilljam H, Malmborg A-S, Strandvik B: Conformity of bacterial growth in sputum and contamination—free endobronchial samples in patients with cystic fibrosis. Thorax 41: 641–646, 1986
  • Strandvik B, Malmborg A-S, Bergan T, Michalsen H, Storrøsten OT, Wretlind B. Imipenem/cilastatin, an alternative treatment of Pseudomonas infection in cystic fibrosis. J Antimicrob Chemother 21: 471–480, 1988
  • Goldfarb J, Stern RC, Reed MD, Yamashita TS, Myers CM, Blumer JL. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. Am J Med 82, Suppl 4 A: 174–179, 1987
  • Shalit I, Stutman HR, Marks MI, Chartrand SA, Hilman BC. Randomized study of two dosages regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am J Med 82, Suppl A: 189–195, 1987
  • Van den Broek PJ, Bakker W, Mattie H, van Gulpen C. The use of ciprofloxacin in the treatment of patients with cystic fibrosis. Pharm Week Sci Ed 9, Suppl: S68–70, 1987
  • Wingender W, Graefe K-H, Gan W, Förster D, Beermann D, Schacht P. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol 3: 355–359, 1984
  • Krutzén E, Bäck SE, Nilsson-Ehle I, Nilsson-Ehle P. Plasma clearance of a new contrast agent, iohexol: A method for the assessment of glomerular filtration rate. J Lab Clin Med 104: 955–961, 1984
  • Nilsson-Ehle I. Assay of ciprofloxacin and norfloxacin in serum and urine by high-performance liquid chromatograpy. J Chromatography Biomed Applic 416: 207–211, 1987
  • Gibaldi M. Noncompartmental pharmacokinetics. In: Biopharmaceutics and clinical pharamaco-kinetics, 3rd ed. Philadelphia: Lea & Febiger, 17–28, 1984
  • Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of intravenous ciprofloxacin at three different doses. J Antimicrob Chemother 22: 715–720, 1988
  • Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, Smith AL. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 31: 915–919, 1987
  • Scully BE, Neu HC. Treatment of serious infections with intravenous ciprofloxacin. Am J Med 82, Suppl 4A: 369–375, 1987
  • Strandvik B, Malmborg A-S, Alfredsson H and Ericsson A. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J Antimicrobiol Chemother. 12: Suppl A, 283–7, 1983

References

  • Friis-Møller A, Rechnitzer C, Black FT, Collins MT, Lind K, Aalund O. Prevalence of Legionnaires Disease in pneumonia patients admitted to a Danish department of infectious diseases. Scand J Infect Dis 18: 321–328, 1986
  • Holmberg H. Aetiology of community acquired pneumonia in hospital treated patients. Scand J Infect Dis 19: 491–501, 1987
  • Chodosh S. Acute bacterial exacerbations in bronchitis and asthma. Am J Med 82 ( Suppl 4 A): 154–163, 1987
  • Powell M, Koutsia-Carouzou C, Voutsinas D, Seymour A, Williams JD. Resistance of clinical isolates of Haemophilus influenzae in United Kingdom 1986. Br Med J 195: 176–179, 1987
  • Editorial. Antibiotics for exacerbations of chronic bronchitis? Lancet ii: 23–24, 1987
  • King A, Phillips I. The comparative in-vitro activity of eight newer quniolones and nalidixic acid. J Antimicrob Chemother 18 ( Suppl D): 1–20, 1986
  • Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother 23: 559–564, 1983
  • Ruckdeschel G, Ehret W, Ahl A. Susceptibility of Legionella spp. to quinolone derivatives and related organic acids. Eur J Clin Microbiol 3: 26, 1984
  • Brunner H, Zeiler H-J. Efficacy of ciprofloxacin in Mycoplasma pneumoniae infection of hamsters. In: Neu HC, Weuta H, eds. Proceedings of the 1st International Ciprofloxacin Workshop, pp. 77–81, Excerpta Medica, Amsterdam, 1986
  • Young LS, Berlin OGW, Inderlied CB. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med 82 ( Suppl 4 A): 23–26, 1987
  • Wolfson JS, Hooper DC. The fluoroquniolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 28: 581–586, 1985
  • Baltimore R, Christie C, Smith GJW. Immunohistopathologic localization of Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. Pediatr Pulmonol Suppl 2: 114, 1988
  • Davies BI, Maesen FPV, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol 5: 226–231, 1986
  • Pedersen SS, Jensen T, Hvidberg EF. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. J Antimicrob Chemother 20: 575–583, 1987
  • Thys JP, Klastersky J, Jacobs F, Berre J, Gangji D, Hanotte F, Serruys E. Penetration of ciprofloxacin into bronchial secretions and pleural fluid. In: Neu HC, Weuta H, eds. Proceedings of the 1st International Ciprofloxacin Workshop, pp. 153–156, Excerpta Medica, Amsterdam, 1986
  • Schlenkoff D, Dalhoff A, Knopf J, Opferkuch W. Penetration of ciprofloxacin into human lung tissue following intravenous injection. Infection 14: 299–300, 1986
  • Honeybourne D, Wise R, JM Andrews. Ciprofloxacin penetration into lungs. Lancet i: 1040, 1987
  • Bergogne-Berezin E, Berthelot G, Even P, Stern M, Reynaud P. Penetration of ciprofloxacin into bronchial secretions. Eur J Clin Microbiol 5: 197–200, 1986
  • Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, Smith A. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 31: 915–919, 1987
  • Smith MJ, White LO, Bowyer H, Willis J, Hodson ME, Batten JC. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother 30: 614–616, 1986
  • Hoogkamp-Korstanje JAA, Klein SJ. Ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 18: 407–413, 1986
  • Easmon CSF, Crane JP. Uptake of ciprofloxacin by human neutrophils. J Antimicrob Chemother 16: 67–73, 1985
  • Goldfarb J, Wormser GP, Inchiosa MA, Guideri G, Diaz M, Gandhi R, Goltzman C, Mascia AV. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J Clin Pharmacol 26: 222–226, 1986
  • LeBel M, Bergeron MG, Vallee F, Fiset C, Chasse G, Bigonesse P, Rivard G. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 30: 260–266, 1986
  • Stutman HR, Shalit I, Marks MI, Greenwood R, Chartrand SA, Hilman BC. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. Am J Med 82 ( Suppl 4A): 142–145, 1987
  • Jensen T, Pedersen SS, Nielsen CH, Høiby N, Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother 20: 585–594, 1987
  • Raoof S, Wollschlager C, Khan FA. Ciprofloxacin increases serum levels of theophylline. Am J Med 82 ( Suppl 4 A): 115–118, 1987
  • Wijnands WJA, Vree TB, van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 22: 677–683, 1986
  • Stille W, Harder S, Mieke S, Beer C, Shah PM, Frech K, Staib AH. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother 20: 729–734, 1987
  • Gleadhill IC, Ferguson WP, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. J Antimicrob Chemother 18 ( Suppl D): 133–138, 1986
  • Feist H, Vetter N, Drlicek M, Otupal I, Weuta H. Comparative study of ciprofloxacin and cefalexin in the treatment of patients with lower respiratory tract infections. In: Neu HC, Weuta H, eds. Proceedings of the 1st International Ciprofloxacin Workshop, pp. 265–267, Excerpta Medica, Amsterdam, 1986
  • Hara H, Saito A, Yamaguchi K, Suzuyama Y, Shigeno Y, Kohno S. Comparative study of Bay 09867 (ciprofloxacin) and bacampicillin on bacterial pneumonia by double blind method. Chemotherapy 34: 629–653, 1986
  • Kobayashi H, Takamura H, Takeda H, Kono K, Saito A. Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections. Chemotherapy 34: 1011–1037, 1986
  • Magnani C, Fregni S, Valli G, Cosentina R, Bisetti A. Comparative clinical study of ciprofloxacin and co-trimoxazole in respiratory tract infections. In: Neu HC, Weuta H, eds. Proceedings of the 1st International Ciprofloxacin Workshop, pp. 260–264, Excerpta Medica, Amsterdam, 1986
  • Bantz P-M, Grote J, Peters-Haertel W, Stahmann J, Timm J, Kasten R, Bruck H. Low-dose ciprofloxacin in respiratory tract infections. A randomized comparison with doxycycline in general practice. Am J Med 82 ( Suppl 4A): 208–210, 1987
  • Gellerman H-J. Therapie von unteren Atemwegsinfektionen mit Ciprofloxacin. Medizinische Welt 38: 69–72, 1987
  • Wollschlager CM, Raoof S, Khan FA, Guarneri JJ, LaBombardi V, Afzal Q. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. Am J Med 82 ( Suppl 4 A): 164–168, 1987
  • Lode H, Wiley R, Höffken G, Wagner J, Borner K. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother 31: 1491–1496, 1987
  • Abbas AMA, Hughes C, Thakkar BC, Dongaonkar PP, Tillotson G. Ciprofloxacin versus amoxycillin in the treatment of lower respiratory infection in general practice. Abstract, 2nd International Symposium on New Quinolones, Geneva, p. 208, 1988
  • Haddow AD, Greene SA, Wantuck DK, Heinz GJ. Ciprofloxacin (iv/po) vs. ceftazidime in the treatment of lower respiratory infections. Abstract, 2nd International Symposium on New Quinolones, Geneva, p. 206, 1988
  • Khan F, Basir R, Afzal Q. Controlled, comparative study of low-dose ciprofloxacin versus ampicillin in the treatment of bacterial respiratory tract infections. Abstract, 2nd International Symposium on New Quinolones, Geneva p. 215, 1988
  • Fitzgeorge RB, Baskerville A, Featherstone ASR. Treatment of experimental Legionnaires' disease by aerosol administration of rifampicin, ciprofloxacin and erythromycin. Lancet 8479: 502–503, 1986
  • Havlichek D, Pohlod D, Saravolatz L. Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophilia pneumonia. J Antimicrob Chemother 20: 875–881, 1987
  • Sanders CC, Sanders Jr WE, Goering RV. Overview of preclinical studies with ciprofloxacin. Am J Med 82 ( Suppl 4 A): 2–11, 1987
  • Scully B, Neu HC, Parry MF, Mandell W. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet i: 819–822, 1986
  • Giamarellou H, Galanakis N, Dendrinos C, Stefanou J, Daphnis E, Daikos GK. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 5: 232–235, 1986
  • Campoli-Richard DM, Monk JP, Proce A, Benfield P, Todd PA, Ward A. Ciprofloxacin. A review of its antibacterial acitivity, pharmacokinetic properties and therapeutic use. Drugs 35: 373–447, 1988
  • Shalit I, Stutman H, Marks MI, Chartrand SA, Hilman BC. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am J Med 82 ( Suppl 4 A): 189–195, 1987
  • Hodson ME, Roberts CM, Butland RJA, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intraveous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet i: 235–237, 1987
  • Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients wit cystic fibrosis. Am J Med 82 ( Suppl 4 A): 180–184, 1987
  • Kurz CC, Marget W, Harms K, Bertele RM. Crossover study on the efficacy of oral ofloxacin and ciprofloxacin. Infection 14 ( Suppl 1): S82–S86, 1986
  • Jensen T, Pedersen SS, Høiby N, Koch C. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. Eur J Clin Microbiol 6: 618–622, 1987

References

  • Heimdahl A, Nord CE. Colonization of the oropharynx with pathogenic microorganisms—a potential risk factor for infection in compromised patients. Chemotherapy 4: 186–191, 1985
  • Tancrède C, Andremont A. Bacterial translocation and Gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 152: 99–103, 1985
  • van der Waaij D. Colonization pattern of the digestive tract by potentially pathogenic microorganisms: Colonization-controlling mechanisms and consequences for antibiotic treatment. Infection 11, Suppl 2: 90–92, 1983
  • Nord CE, Kager L, Heimdahl A. Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am J Med 76: 99–106, 1984
  • Nord CE, Heimdahl A, Kager L, Malmborg AS. The impact of different antimicrobial agents on the normal gastrointestinal microflora of humans. Rev Infect Dis 6: 270–275, 1984
  • Sleijfer D Th, Mulder NH, de Vries-Hospers HG, Fidler V, Nieweg HO, van der Waaij D, van Saene HKF. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer 16: 859–869, 1981
  • Guiot HFL, van der Meer JWM, van Furth R. Selective antimicrobial modulation of human microbial flora: Infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria. J Infect Dis 143: 644–654, 1981
  • Shannon K, Phillips I. The antimicrobial spectrum of the quinolones. Clin Res Forum 7: 29–36, 1985
  • Bergan T, Dalhoff A, Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection 16: 3–13, 1988
  • Brumfitt W, Franklin I, Grady D, Hamilton-Miller JMT, Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 26: 757–761, 1984
  • Enzensberger R, Shah PM, Knothe H. Impact of oral ciprofloxacin on the faecal flora of healthy volunteers. Infection 13: 273–275, 1985
  • Holt HA, Lewis DA, White LO, Bastable SY, Reeves DS. Effect of oral ciprofloxacin on the faecal flora of healthy volunteers. Eur J Clin Microbiol 5: 201–205, 1986
  • Bergan T, Delin C, Johansen S, Kolstad IM, Nord CE, Thorsteinsson SB. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and faecal microflora. Antimicrob Agents Chemother 29: 298–302, 1986
  • van Saene JJM, van Saene HKF, Geitz JN, Tarko-Smit NJP, Lerk CF. Quinolones and colonization resistance in human volunteers. Pharm Weekbl (Sci) 8: 67–71, 1986
  • Esposito S, Barba D, Galante D, Gaeta GB, Laghezza O. Intestinal microflora changes induced by ciprofloxacin and treatment of portal-systemic encephalopathy. Drugs Exptl Clin Res 10: 641–646, 1987
  • De Vries-Hospers HG, Welling GW, van der Waaij D. Influence of quinolones on throat and faecal flora of healthy volunteers. Pharm Weekbl (Sci) 9: 41–44, 1987
  • Daikos G, Kathpalia S, Sharifi R, Lolans V, Jackson G. Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. Am J Med 82: 290–294, 1987
  • Scully B, Jules K, Chin N, Neu H. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. Am J Med 82: 336–338, 1987
  • Rozenberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment. The effect on the fecal flora. J Infect Dis 152: 104–107, 1985
  • Dekker A, Rozenberg-Arska M, Verhoef J. Infection propylaxis in acute leukemia: A comparison of ciprofloxacin with trimethoprim sulfamethoxazole and colistin. Ann Int Med 106: 7–12, 1987
  • Dennig D, Fülle H, Hellriegel K. Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin. Onkologie 10: 57–58, 1987

References

  • Grabe M. Short antibiotic courses in transurethral prostatic resection. Scand J Urol Nephrol, Suppl 78, 1984 (thesis).
  • Grabe M. Antimicrobial agents in transurethral prostatic resection. J Urol 138: 245–252, 1987
  • Forsgren A. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates. Scand J Infect Dis 17: 91–94, 1985

References

  • Mäkelä P, Käyhty H, Weckström P, Sivonen A, Renkonen O-V. Effect of group A meningococcal vaccine in army recruits in Finland. Lancet 2: 883–886, 1975
  • Kuhns DW, Nelson CT, Feldman HA, Kuhns LR, The prophylactic value of sulfadiazine in the control of meningococcic meningitis. JAMA 123: 335–339, 1943
  • Deal WB, Sanders E. Efficacy of rifampin in treatment of meningococcal carriers. N Engl J Med 281: 641–645, 1969
  • Sivonen A, Renkonen O-V, Weckström P, Koskenvuo K, Raunio V, Mäkelä P. The effect of chemoprophylactic use of rifampicin and minocycline on rates of carriage of Neisseria meningitidis in army recruits in Finland. J Infect Dis 137: 238–244, 1978
  • Weidmer CE, Dunkel TB, Pettyjohn FS, Smith CD, Leibovitz A. Effectiveness of rifampin in eradicating the meningococcal carrier state in a relatively closed population: emergence of resistant strains. J Infect Dis 124: 172–178, 1971
  • Cooper ER, Ellison RT, Smith GS, Blaser MJ, Reller LB, Paisley JW. Rifampin-resistant meningococcal disease in a contact patient given prophylactic rifampin. J Pediatr 108: 93–96, 1986
  • Barry AL, Jones RN, Thornsberry G, Ayers LW, Gerlach EH, Sommers HM. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin and nalidixic acid. Antimicrob Agents Chemother 25: 633–637, 1984
  • Gonzales MA, Uribe F, Duran Moisen S, Fuster AP, Selen A, Welling PG, Painter B. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26: 741–744, 1984
  • Falser N, Dahlhoff A, Weuta H. Ciprofloxacin concentrations in tonsils following single or multiple administrations. Infection 16, Suppl 1: 355–357, 1988
  • Oriel JD. Ciprofloxacin in the treatment of gonorrhoea and non-gonococcal urethritis. J Antimicrob Chemother 18 Suppl D: 129–132, 1986
  • Renkonen O-V, Sivonen A, Visakorpi R. Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland. Antimicrob Agents Chemother 31: 962–963, 1987
  • Pugsley MP, Dworzack DL, Horowitz EA, Cuevas TA, Sanders WE, Sanders CC. Efficacy of ciprofloxacin in the treatment of nasopharyngeal carriers of Neisseria meningitidis. J Infect Dis 156: 211–212, 1987
  • Pugsley MP, Dworzack DL, Roccaforte JS, Sanders CC, Bakken JS, Sanders WE. An open study of the efficacy of a single dose ciprofloxacin in eliminating the chronic nasopharyngeal carriage of Neisseria meningitidis. J Infect Dis 157: 852–853, 1988
  • Gaunt PN, Lambert BE. Single dose ciprofloxacin for the eradication of pharyngeal carriage of Neisseria meningitidis. J Antimicrob Chemother 21: 489–496, 1988

References

  • Buchwald DS, Blaser MJ. A review of human Salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev Infect Dis 6: 345–356, 1984
  • Freitag JL. Treatment of chronic typhoid carriers by cholecystectomy. Publ Health Rep 79: 567–570, 1964
  • Vogelsang TM. The campaign against typhoid and parathyroid B in western Norway. Results of cholecystectomy. J Hyg 62: 443–449, 1964
  • Pettersson T. Effekten av penicillin i stora doser på Salmonella-bacillbärare. Nord Med 69: 665–668, 1963
  • Pettersson T, Klemola E, Wager O. Treatment of acute cases of Salmonella infection and Salmonella carriers with ampicillin and neomycin. Acta Med Scand 175: 185–190, 1964
  • Dinbar A, Altmann G, Tulcinsky DB. The treatment of chronic biliary Salmonella carriers. Am J Med 47: 236–242, 1969
  • Iwarson S. Long-term co-trimoxazole treatment of chronic Salmonella carriers. Scand J Infect Dis 9: 297–299, 1977
  • Alkio L. Salmonellankantajien hoito trimetopriimin ja sulfametoksatsolin yhdistelmällä. Suom Lääkäril 32: 695–699, 1977
  • Freerksen E, Rosenfeld M, Freerksen R, Krueger-Thiemer M. Treatment of chronic Salmonella carriers. Chemotherapy 23: 192–210, 1977
  • Ekwall E, Jonsson M. A comparison of the combination pivmecillinam/pivampicillin and co-trimoxazole in the treatment of convalescent carriers of Salmonella and Shigella. Scand J Infect Dis 16: 99–102, 1984
  • Soe GB, Overturf GD. Treatment of typhoid fever and other systemic Salmonelloses with cefotaxime, ceftriaxone, cefoperazone, and other newer cephalosporins. Rev Infect Dis 9: 719–736, 1987
  • Bryan JP, Rocha H, Scheld WM. Problems in Salmonellosis: rationale for clinical trials with newer beta-lactam agents and quinolones. Rev Infect Dis 8: 189–207, 1986
  • Goodman LJ, Fliegeman RM, Trenholme GM, Kaplan RL. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens. Antimicrob Agents Chemother 25: 504–506, 1984
  • Hudson SJ, Ingham HR, Snow MH. Treatment of Salmonella typhi carrier state with ciprofloxacin. Lancet i: 1047, 1985
  • Diridl G, Pichler H, Wolf D. Treatment of chronic Salmonella carriers with ciprofloxacin. Eur J Clin Microbiol 5: 260–261, 1986
  • Sammalkorpi K, Lähdevirta J, Mäkelä T, Rostila T. Treatment of chronic Salmonella carriers with ciprofloxacin. Lancet ii: 164–165, 1987
  • Sammalkorpi K, Lähdevirta J, Mäkelä T, Rostila T. Siprofloksasiini—olennainen parannus salmonellankantajien hoitoon. Suom Lääkäril 30: 2784–2786, 1987
  • Reid T, Smith C. Ciprofloxacin treatment of chronic Salmonella excretors. Chemioterapia 6: Suppl. 2: 485–486, 1987

References

  • Giamarellou H, Galanakis N. Intravenous ciprofloxacin in difficult-to-treat infections. Am J Med 82 (Suppl 4 A): 346–351, 1987
  • Scully BE, Neu HC. Treatment of serious infections with intravenous ciprofloxacin. Am J Med 82 (Suppl 4 A): 369–375, 1987
  • Chrysanthopoulos CJ, Skoutelis AT, Starakis JC, Anastassiou ED, Bassaris HP. Use of intravenous ciprofloxacin in respiratory tract infections and biliary sepsis. Am J Med 82 (Suppl 4 A): 357–359, 1987
  • Beam TR, Guitierrez I, Powell S, Hewitt R, Hocko M, Brackett M, Craver M. Prospective study of the efficacy and safety of ciprofloxacin iv/po in the treatment of diabetic foot infections. 2nd Internat Symposium on new Quinolones. Geneva. Aug. 25–27, 1988. Abstract no. 176.
  • Modai J, and the French Multicenter Study Group. Treatment of serious infections with intravenous Ciprofloxacin. 2nd Internat Symposium on new Quinolones. Geneva. Aug. 25–27, 1988. Abstract no. 187.
  • Nix DE, Peloquin CA, Cumbo TJ, Sands MF, Schentag JJ. Intravenous ciprofloxacin for nosocomial lower respiratory tract infections. 2nd Internat Symposium on new Quinolones. Geneva. Aug. 25–27, 1988. Abstract no. 211.
  • Haddow AD, Greene SA, Wantuck DK, Heinz GJ. Ciprofloxacin (iv/po) vs. ceftazidime in the treatment of lower respiratory infections. 2nd Internat Symposium on new Quinolones. Geneva. Aug. 25–27, 1988. Abstract no. 206.
  • Meyers BR, Mendelson MH, Hirschman SZ. Parenteral/oral eiprofloxacin for the treatment of serious infections. 2nd Internat Symposium on new Qunolones. Geneva. Aug. 25–27, 1988. Abstract no. 174.
  • Garau J, Bouza E, Sanmiguel JG, Gudiol F, Honorato J, Ingelmo JP. Initial intravenous ciprofloxacin therapy for the treatment of serious infections caused by Ps. aeruginosa and other gramnegative bacilli. An analysis of 73 patients. 15th Internat Congr of Chemother. Istanbul. July 19–24, 1987. Abstract no. 74.
  • Suwangool P, Vichvanives P, Moolaor P. Intravenous ciprofloxacin in moderate to severe infections. 2nd Internat Symposium on new Quinolones. Geneva. Aug. 25–27, 1988. Abstract no. 173.
  • Timerman A, Hutzler RU. Treatment of systemic and localized infections with ciprofloxacin, results of an open prospective study in Brasil. 2nd Internat Symposium on new Quinolones. Geneva. Aug. 25–27, 1988. Abstract no. 165.
  • Plaza de Los Reyes M, Castro J, Saffie J. Ciprofloxacin experience in twenty patients treated in the University Clinic of the Universidad de Chile. 2nd Internat Symposium on new Quinolones. Geneva. Aug. 25–27, 1988. Abstract no. 161.
  • Greco TP, Simms M, Mangi R, Ryan J, Thornton G, Andriole VT. Ciprofloxacin intravenous followed by oral treatment of various systemic infections. 2nd Internat Symposium on new Quinolones. Geneva. Aug. 25–27, 1988. Abstract no. 154.
  • Rolston K, Haron E, Cunningham C, Bodey GP. Ciprofloxacin for infections in cancer patients. 2nd Internat Symposium on new Quinolones. Geneva. Aug. 25–27, 1988. Abstract no. 14.
  • Thorsteinsson SB, Bergan T, Johannesson G, Thorsteinsson HS, Rohwedder R. Tolerance of ciprofloxacin at injection site, systemic safety and effect on electroencephalogram. Chemotherapy 33: 448–451, 1987
  • Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy 34: 256–260, 1988
  • Thorsteinsson SB, Rohwedder R, Rahm V, Bergan T. Tolerance of infusions of ciprofloxacin. Internat Congr for Infectious Dis. Rio de Janeiro April 17–21, 1988. Abstract no. 574.
  • Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 32: 408–417, 1986

References

  • Schacht P, Arcieri G, Branolte J, Bruck H, Chyský V, Griffith E, Gruenwaldt G, Hullman R, Konopka CA, O'Brien B, Rahm V, Ryoki T, Westwood A, Weuta H. Worldwide clinical data on efficacy and safety of ciprofloxacin. Infection Suppl I, 16: 29–43, 1988
  • Arcieri G, August R, Becker N, Doyle C, Griffith E, Gruenwaldt G, Heyd A, O'Brien B. Clinical experience with ciprofloxacin in the USA. Eur J Clin Microbiol 5, 2: 220–225, 1986
  • Tatsumilt, Senda H, Yaterer S, Tekemoto Y, Yamayoshi M, Ohnishi K. Toxicological studies on pipermidic acid. V. Effect on diarthrodial joint of experimental animals. J Toxicol Sci 3: 357–367, 1978
  • Grough A, Barsoum N, Mitchell L, Mc'Gurie EJ, Felix A, Iglesia DL. Juvenile canine drug-induced arthropathy: Clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 51: 177–189, 1979
  • Stahlman R, Blankenburg G, Neubert D. Studies on cartilage formation and differentiation in limb-bud culture in the presence of nalidixic acid, ofloxacin and ciprofloxacin. Rev Infect Dis 10, Suppl 1: 147, 1988
  • Gauet MH, Cockcroft DW. Creatinine clearance and age. Lancet 2: 612–613, 1976
  • Shah PM, Mulert R. Safety of quinolones: Analysis of clinical trials and post-marketing survey data. 2nd International Symposium on New Quinolones. Abstract pg 339, 1988
  • Lode H. Drug interactions with quinolones. Rev Infect Dis 10, Suppl 1: 132–136, 1988
  • Rybak MJ, Bowles SK, Chandrasekar PH, Edwards DJ. Increased theophylline concentrations secondary to ciprofloxacin. Drug Intell Clin Pharm 21: 879–881, 1987
  • Christ W, Lehnert T, Ulbrich B. Specific toxicological aspects of the quinolones. Rev Infect Dis 10, Suppl 1: 141–146, 1988
  • Morikawa K, Nagata O, Kubo S, Kato H, Yamamoto K. Abstracts of the 1987 ICAAC. Abstract no 255 pg 141, 1987
  • Eliopoulos GM. New Quinolones: Pharmacology, pharmacokinetics, and dosing in patients with renal insufficiency. Rev Infect Dis 10, Suppl 1: 102–105, 1988
  • Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy 32: 408–417, 1986

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.